Gregory T. Lucier
Gregory T. Lucier's purchase track record
How the stock did after each of Gregory T. Lucier's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | AVTR | $83K | +63.5% | pending | — |
| 3/2/2026 | XRAY | $894K | -30.0% | -21.9% | +11.7% |
| 2/19/2026 | AVTR | $458K | -14.5% | +54.7% | +11.4% |
| 12/5/2025 | MRVI | $369K | -4.0% | +35.7% | +7.5% |
| 3/3/2025 | XRAY | $250K | -1.3% | -11.9% | +9.7% |
| 11/15/2024 | XRAY | $110K | +1.1% | -6.9% | +1.5% |
| 8/8/2024 | XRAY | $200K | -28.7% | -19.9% | +14.4% |
| 5/31/2024 | XRAY | $100K | -9.1% | -29.0% | +14.3% |
| 11/22/2023 | XRAY | $314K | +5.9% | -9.8% | +16.5% |
| 11/15/2022 | XRAY | $189K | +18.5% | +30.0% | +3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Avantor to Report Q3 2026 Earnings on October 28. Avantor has scheduled its third-quarter 2026 earnings release for Wednesday, October 28, 2026. Recent coverage notes that the company led peer groups in research tools and consumables during the second quarter. The stock is currently trading near the lower end of its 52-week range, with analysts maintaining a wide target price spread.
Transaction History
| MRVI | ▼ Sell | Gift | 46,293 | $0 | 6/9/2026 | View on chart |
| MRVI | ▼ Sell | Gift | 46,293 | $0 | 6/9/2026 | View on chart |
| XRAY | ▼ Sell | Gift | 38,382 | $0 | 6/3/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 38,382 | $0 | 6/3/2026 | View on chart |
| XRAY | ▼ Sell | Gift | 38,382 | $0 | 6/3/2026 | View on chart |
| MRVI | ▲ Buy | Grant | 46,293 | $203K | 5/26/2026 | View on chart |
| AVTR | ▲ Buy | Open Market | 10,000 | $83K | 5/8/2026 | View on chart |
| AVTR | ▲ Buy | Grant | 25,270 | $0 | 5/7/2026 | View on chart |
| XRAY | ▲ Buy | Open Market | 15,000 | $187K | 3/9/2026 | View on chart |
| XRAY | ▲ Buy | Open Market | 22,445 | $315K | 3/3/2026 | View on chart |
| XRAY | ▲ Buy | Open Market | 27,555 | $393K | 3/2/2026 | View on chart |
| AVTR | ▲ Buy | Open Market | 50,000 | $458K | 2/19/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 341 | $0 | 1/9/2026 | View on chart |
| MRVI | ▲ Buy | Open Market | 48,528 | $178K | 12/8/2025 | View on chart |
| XRAY | ▼ Sell | Open Market | 82,200 | $916K | 12/8/2025 | View on chart |
| MRVI | ▲ Buy | Open Market | 51,472 | $190K | 12/5/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 310 | $0 | 10/10/2025 | View on chart |
| AVTR | ▲ Buy | Grant | 8,736 | $0 | 10/3/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 3,858 | $0 | 8/8/2025 | View on chart |
| XRAY | ▼ Sell | Gift | 24,047 | $0 | 8/8/2025 | View on chart |
| XRAY | ▼ Sell | Gift | 24,047 | $0 | 8/8/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 203 | $0 | 7/11/2025 | View on chart |
| MRVI | ▼ Sell | Gift | 89,139 | $0 | 7/10/2025 | View on chart |
| MRVI | ▼ Sell | Gift | 89,139 | $0 | 7/10/2025 | View on chart |
| MRVI | ▲ Buy | Grant | 89,139 | $193K | 6/16/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 20,189 | $0 | 5/22/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 127 | $0 | 4/11/2025 | View on chart |
| XRAY | ▲ Buy | Open Market | 15,142 | $250K | 3/3/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 99 | $0 | 1/10/2025 | View on chart |
| MRVI | ▼ Sell | Gift | 20,645 | $0 | 12/9/2024 | View on chart |
| MRVI | ▼ Sell | Gift | 20,645 | $0 | 12/9/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 5,000 | $92K | 11/18/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 1,000 | $18K | 11/15/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 69 | $0 | 10/11/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 8,212 | $200K | 8/8/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 75 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 3,577 | $100K | 5/31/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 11,628 | $0 | 5/23/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 20,645 | $223K | 5/23/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 26 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 21 | $0 | 1/12/2024 | View on chart |
| XRAY | ▲ Buy | Open Market | 10,000 | $314K | 11/22/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 49 | $0 | 10/13/2023 | View on chart |
| MRVI | ▲ Buy | Grant | 24,000 | $0 | 7/17/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 41 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 5,419 | $0 | 5/25/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 23 | $0 | 4/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 25 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Open Market | 6,000 | $189K | 11/15/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6,382 | $0 | 11/15/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 8 | $0 | 4/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $0 | 1/14/2022 | View on chart |
| MRVI | ▲ Buy | Grant | 4,271 | $0 | 11/19/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $331 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript
Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.